Auro Laboratories reported a decisive shift from loss to profit in its standalone financial results for the quarter ended June 30, 2026. The pharma company posted a net profit of ₹104.56 lakh, reversing a net loss of ₹10.55 lakh recorded in the same quarter of FY25. This turnaround was underpinned by a substantial surge in top-line growth, with total income from operations rising 178% year-on-year to ₹887.64 lakh from ₹319.07 lakh.

The Board of Directors approved the unaudited financial results at its meeting held on August 14, 2026. The figures have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The statutory auditors conducted a limited review of the financial results, issuing an unqualified report with no adverse remarks or modifications required.

Financial Performance Overview

The company’s operational efficiency improved markedly during the period. Before tax and exceptional items, the net profit stood at ₹113.04 lakh, compared to a loss of ₹10.55 lakh in the prior year’s quarter. Earnings per share (EPS) also reflected this recovery, climbing to ₹1.68 per equity share from a negative ₹0.17 in the corresponding period of FY25.

For the full fiscal year ended March 31, 2026, Auro Laboratories reported a total income from operations of ₹3,274.91 lakh and a net profit after tax of ₹353.29 lakh. The company maintains a single reportable business segment, focusing exclusively on pharmaceuticals.

What the Numbers Show

The divergence between the pre-tax profit of ₹113.04 lakh and the post-tax profit of ₹104.56 lakh indicates a tax expense of approximately ₹8.48 lakh for the quarter. Given the magnitude of the income surge, the effective tax impact remains relatively contained, suggesting that the bulk of the additional revenue translated directly into bottom-line gains. The reversal from a negative EPS of ₹0.17 to a positive ₹1.68 highlights the sensitivity of the company’s profitability metrics to operational volume changes during this period.

Auro Laboratories Limited has scheduled its 37th Annual General Meeting (AGM) for Tuesday, August 11, 2026, at 11:30 a.m. IST. The meeting will be conducted through video conferencing (VC) or other audio-visual means (OAVM) in compliance with the Companies Act, 2013, and SEBI Listing Regulations. The company has dispensed with the requirement to send physical copies of the Annual Report for FY 2025-2026 to members, opting instead for electronic distribution to those with registered email addresses.

The Notice of the 37th AGM and the Integrated Annual Report for FY 2025-2026 will be sent electronically to members whose email addresses are registered with the company, its Registrar & Transfer Agents (RTA), or Depository Participant. Physical copies of the report will be dispatched only to members who specifically request them by emailing cs@aurolabs.com with their Folio Number or DPID and Client ID. These documents will also be available on the company's website and the BSE Limited website.

Auro Laboratories Limited has provided an e-voting facility through CDSL, allowing members to cast votes remotely before and during the AGM. Members can attend and participate in the meeting exclusively through the VC/OAVM facility. Detailed instructions regarding remote e-voting and virtual meeting attendance will be included in the official notice convening the meeting. Members attending via VC/OAVM will be counted for the purpose of quorum under Section 103 of the Companies Act, 2013.

The company has advised members holding shares in physical form to register their email addresses with the company or RTA to receive electronic communications. Those holding shares in demat form must update their email IDs and mobile numbers with their respective Depository Participants to facilitate e-voting and participation in virtual meetings.

Key Meeting Details